The mTOR inhibitor rapamycin exhibits metabolic effects akin to those of glycolysis inhibitors in CRC, and when used in conjunction with oxamate, it synergistically enhances survival rates and therapeutic efficacy in CRC patients [233]. The gene discussed is MTOR; the disease is colorectal carcinoma.